Doug Manion, M.D., FRCP (C)
Chairman of the Board

Doug has over 20 years’ experience in drug development. He is currently the Chief Executive Officer, and Director, Flare Therapeutics . Previously, he served as Chief Executive officer or Aclaris Therapeutics and before that Executive Vice President of Research and Development for Arena Pharmaceuticals, a publicly traded (ARNA, NASDAQ) company focused on immunotherapeutic and cardiovascular disease. Until January 2021, he was CEO of Kleo Pharmaceuticals, a private biotech company spun out of Yale University that was acquired by Biohaven Holdings (BHVN, NYSE). Previously, he was the Senior Vice President and Head of Specialty Development, and Head of Japan and China R&D at Bristol Myers-Squibb (BMY.NYSE) until October 2016. He had leadership roles at BMS overseeing various therapeutic areas including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically defined diseases, and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GlaxoSmithKline (GSK, NYSE). He started his career at DuPont Pharmaceuticals in 1997. He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa Canada and a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School.

Leonard J. DeRoma
Director

Mr. DeRoma began his career in the 1970s at Citibank’s corporate finance department in strategic planning, private placements. and mergers and acquisitions. He helped pioneer one of the first strategic planning services for Citibank corporate finance clients. He then spent the next 20 years in senior positions in fixed-income trading for a several financial institutions, including Citibank, Lehman Brothers, Barclays Capital, and KeyBank-McDonald Investments, managing large components of their domestic and foreign fixed-income trading, sales, derivatives, research, underwritings, and foreign exchange businesses. He served as the President of Barclay’s U.S. securities business, was senior advisor to the U.S. Asset Liability Committee, and chaired the U.S. Credit and Risk Management Committee.

Mr. DeRoma returned to corporate finance, forming Wildwood Capital LLC, a small boutique advisory firm focused on strategic advice, mergers and acquisitions, and fund-raising for small and middle-market companies. He later was a founding partner of Invictus Consulting Group, an advisory company oriented towards the strategic needs of community banks. In addition, he has served as a director of several public and private companies and funds. He has also served on several industry boards and associations, including the Public Securities Association and the Bond Market Association. He is Chairman of the Board of SN2N LLC, an early stage cybersecurity company. He has been a speaker at numerous conferences on credit, liquidity and markets in the U.S., Europe and Asia. Mr. DeRoma has a B.S. in Electrical Engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.

Charles F. Wright
Director

Mr. Wright has had a long and successful career as a businessman and investor. He is the Chairman of The Fall River Group, Inc. a manufacturing organization of foundries located in Wisconsin, He has been associated with Fall River for over 45 years. He serves on the board of Prolitec Inc. and on the advisory board of Total Multimedia, Incorporated. Mr. Wright is a partner and Chairman of Quaestus & Co. Inc., which is a venture capital and private equity firm. He received a BA in Speech from the University of South Florida and an MBA from the Harvard Business School.

Kelvin Cooper
Chief Executive Officer and Senior Vice President, Research and Development

Kelvin is a seasoned pharmaceutical scientist and executive with more than 45 years of experience in all aspects of drug discovery and development across several therapeutic areas including infectious disease, cancer, respiratory, immunology, and inflammation. Before joining Lakewood-Amedex, Kelvin filled several roles at Pfizer from 1981 to 2011, including Senior Vice President for Portfolio Development in their Established Pharmaceutical Sciences Business Unit from 2009 to 2011; Senior Vice President of Worldwide Pharmaceutical Sciences with responsibility for both small molecules and biologics in the areas of drug substance, drug product, and device development from 2000 to 2008; Executive Director of drug development for cancer, respiratory, allergy, immunology, and infectious disease from 1998 to 2000; and Director of Drug Discovery in those same therapeutic areas 1994-1997. Kelvin earned a Ph.D. in Organic Chemistry from the University of Nottingham and is a past recipient of the Captain Black Award for Science. He has also authored 49 publications and holds 34 patents.